Biotechnology News

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives Pelthos gains enhanced commercial coverage through a regional commercial...

Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens...

European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06,...

MANCHESTER, United Kingdom, Oct. 06, 2026 (GLOBE NEWSWIRE) -- F2G Ltd. today announced abstracts accepted for oral and poster presentation at IDWeek 2026, taking place October 21–24, 2026, at the...

Marvel Biosciences’ Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

Company announcement no. 38 - 2606 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026

Rewind Therapeutics secures financing to advance its oral GPR17 remyelination program for MS, supported by peer-reviewed preclinical data in PLOS ONE.

One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event